The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.
about
A Subset of Autism-Associated Genes Regulate the Structural Stability of Neurons.Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study.Multifocal micronodular pneumocyte hyperplasia (MMPH) in a patient with tuberous sclerosis-evidence for long term stability.Epilepsy Mechanisms in Neurocutaneous Disorders: Tuberous Sclerosis Complex, Neurofibromatosis Type 1, and Sturge-Weber Syndrome.Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.Roles of Diffusion Dynamics in Stem Cell Signaling and Three-Dimensional Tissue Development.Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.Coding and small non-coding transcriptional landscape of tuberous sclerosis complex cortical tubers: implications for pathophysiology and treatment.Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma.Knockout of the epilepsy gene Depdc5 in mice causes severe embryonic dysmorphology with hyperactivity of mTORC1 signalling.Expert Opinion on the Management of Lennox-Gastaut Syndrome: Treatment Algorithms and Practical Considerations.Radiobiological Characterization of Tuberous Sclerosis: a Delay in the Nucleo-Shuttling of ATM May Be Responsible for Radiosensitivity.Presentation and Diagnosis of Tuberous Sclerosis Complex in Infants.Effects of everolimus on tuberous sclerosis complex-associated renal angiomyolipoma: A preliminary report.Malignant PEComa With Metastatic Disease at Diagnosis and Resistance to Several Chemotherapy Regimens and Targeted Therapy (m-TOR Inhibitor).mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model.
P2860
Q28079929-5556561E-EF94-42F8-92A0-738B513FD70EQ31140724-703351E4-3986-4525-8458-D0D1FD4D5B4FQ37603932-30D1148B-B15E-4341-9BA2-DD01F7272A81Q37707250-E804D868-27DB-4083-A8F6-BAE07F2D9A1BQ37721031-2EF621BE-5DA9-47BE-BA56-C67B7945502BQ38657727-893D2C71-76BB-4D37-97AC-4784DD02F5DEQ38914374-80D78D4D-167D-4BED-892D-9FCCBA69B2FBQ40083141-914B8D7D-1C29-4536-9A55-531A8503BF10Q41485973-7A779654-9988-44AB-B68D-FB95AC32792CQ41997482-B053C8F9-D2E5-4A75-A3F0-698157F7CB7FQ43004735-A3F56E53-66D0-4563-8EDE-2AC3C1DCEC93Q47980226-68E334E5-83A0-49C4-BEA3-FEBCC6FB37CAQ50174779-0B6B2A97-A8EB-4ECC-9CE6-B948D9298BCEQ53578553-4F21E86B-2E7E-45DD-9A13-B72AF754AFE9Q53619606-D9E923E4-13E1-4C23-BE03-75B686E41F92Q54978861-4ABA871A-D3C0-44C8-A77D-EA5864BE6ACE
P2860
The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The Role of mTOR Inhibitors in ...... nce-based and Expert Opinions.
@en
type
label
The Role of mTOR Inhibitors in ...... nce-based and Expert Opinions.
@en
prefLabel
The Role of mTOR Inhibitors in ...... nce-based and Expert Opinions.
@en
P2093
P2860
P50
P1433
P1476
The Role of mTOR Inhibitors in ...... ence-based and Expert Opinions
@en
P2093
Alfons Macaya
Bernard A Zonnenberg
Christoph Hertzberg
J Christopher Kingswood
José Carlos Ferreira
Marit Bjørnvold
Martha Feucht
Paolo Curatolo
Patricia E Dill
Rima Nabbout
P2860
P2888
P304
P356
10.1007/S40265-016-0552-9
P577
2016-04-01T00:00:00Z
P6179
1019999114